(Reuters) -Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration moves ahead with a 100% tariff on imported branded and patented drugs, starting October 1. The sweeping measure has triggered a flurry of activity across the industry, including fast-tracking U.S. manufacturing projects, price cuts and direct-to-consumer sales. Here's what drugmakers are doing to mitigate supply-chain risks and reassure investors: Pfizer Pfizer re ...

Bristol Myers Squibb , Takeda Pharmaceuticals and Astex Pharmaceuticals are coming together to share proprietary data for training an artificial intelligence model to assist drug discovery and development. ...

Roche Holding and AstraZeneca were among those companies posting increases as European pharma stocks tracked gains in the U.S. on Tuesday. ...

European stocks were mixed on Wednesday as the United States plunged into a government shutdown, a few hours after the Senate failed to pass a short-term spending bill.The pan European Stoxx 600 was up 0.2 percent at 559.42 after rising half a percent on Tuesday to conclude September on a positive note. The German DAX slipped 0.2 percent and France's CAC 40 was marginally lower while the U.K.'s FTSE 100 climbed 0.7 percent after a survey showed U.K. house prices growth accelerated in September amid easing ...

There hasn't been much good news lately for this Johnson & Johnson spinoff.Johnson & Johnson (JNJ 2.05%) spun off its consumer health unit as a separate entity in 2023. The new business, Kenvue (KVUE -0.77%), inherited a broad lineup of popular products, including Band-Aid adhesive bandages, Listerine mouthwash, Tylenol pain reliever, and Zyrtec allergy medicine. With an arsenal of household names in its lineup and a solid dividend, Kenvue seemed to be the kind of stock many income investors would love. How ...

Three supercharged income stocks have the catalysts necessary to pad the pocketbooks of patient investors.For more than a century, the stock market has reigned supreme as the most-decorated wealth creator. No asset class has come close to matching the average annual return of stocks -- and with thousands of publicly traded companies to choose from, there's likely one or more securities that can help you reach your investment goals.But among the countless ways to grow your wealth, buying and holding high-qua ...

European healthcare stocks jumped on Wednesday, a day after Pfizer and U.S. President Donald Trump said the U.S.-based drugmaker agreed to lower prescription drug prices in the Medicaid program in exchange for tariff relief. ...

Ah, the stock market. A fickle beast, swayed by everything from geopolitical tremors to a rogue tweet. But in the grand theater of financial volatility, one performer consistently delivers a unique brand of drama: Donald J. Trump. With a recent flurry of pronouncements, from cinematic tariffs to pharmaceutical pacts, the former (and potentially future) President has once again reminded us that when it comes to market reactions, predictability is, well, entirely unpredictable. It’s a high-stakes game of poli ...

In practice, that means delisting its American Depositary Receipts (ADRs) from the Nasdaq, replacing them with a direct listing of ordinary shares on the New York Stock Exchange.GSK said Emma Walmsley, its CEO of nine years, who steered it through its demerger (its former consumer healthcare arm is now a separate company called Haleon), will leave at the end of the year. Her successor is Luke Miels, currently chief commercial officer, was poached from AZ amid acrimony eight years ago.There is an old British ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 近日，浙江海正药业股份有限公司（以下简称"公司"）收到国家药品监督管理局（以下简称"国家药监 局"）核准签发的他克莫司胶囊《药品补充申请批准通知书》，公司药品他克莫司胶囊已通过仿制药质 量和疗效一致性评价。现就相关情况公告如下： 一、药品的基本情况 药品名称：他克莫司胶囊 剂型：胶囊剂 规格：0.5mg、1mg 注册分类：化学药品 上市许可持有人：浙江海正药业股份有限公司 生产企业：浙江海正药业股份有限公司 2024年12月5日，国家药监局受理了公司递交的他克莫司胶囊一致性评价申请。截至目前，公司针对该 药品仿制药质量和疗效一致性评价已投入约6,144.39万元人民币。 三、对上市公司影响及风险提示 根据国家相关政策，通过一致性评价的药品品种在医保支付及医疗机构采购等领域将获得更大的支持力 度，因此公司的他克莫司胶囊通过仿制药一致性评价，有利于扩大上述药品的市场份额，提升市场竞争 力。 受理号：CYHB2450594、CYHB2450593 通知书编号：2025B04548、20 ...